

# Phase I trial BDD code: BDD22320

<b>Submission date</b> 24/07/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 24/07/2025	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 06/02/2026	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

## Contact information

### Type(s)

Public, Scientific, Principal investigator

### Contact name

Dr Lyn Corry

### ORCID ID

<https://orcid.org/0009-0008-4224-4667>

### Contact details

BDD Pharma Ltd  
Within Glasgow Royal Infirmary  
84 Castle Street  
Glasgow  
United Kingdom  
G4 0SF  
0141 552 8791  
[Lyn.Corry@bddpharma.com](mailto:Lyn.Corry@bddpharma.com)

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Integrated Research Application System (IRAS)

1009022

**Protocol serial number**

MOS118-101

## Study information

**Scientific Title**

Phase I trial BDD code: BDD22320

**Study objectives**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 04/03/2024, London - Brent Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)2071048128; brent.rec@hra.nhs.uk), ref: 24/LO/0003

**Study design**

Pharmacoscintigraphic open-label crossover study

**Primary study design**

Interventional

**Study type(s)**

Other

**Health condition(s) or problem(s) studied**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

**Interventions**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

**Intervention Type**

Drug

**Phase**

Phase I

**Drug/device/biological/vaccine name(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

**Primary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

**Key secondary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

**Completion date**

20/08/2025

**Eligibility****Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

65 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 12 months after the trial has ended.

**Date of first enrolment**

09/06/2025

**Date of final enrolment**

23/06/2025

## Locations

### Countries of recruitment

United Kingdom

Scotland

### Study participating centre

#### BDD Pharma Ltd

Glasgow Royal Infirmary

84 Castle Street

Glasgow

Scotland

G4 0SF

## Sponsor information

### Organisation

Mosanna Therapeutics

## Funder(s)

### Funder type

Industry

### Funder Name

Mosanna Therapeutics

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not expected to be made available